The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score

Geisler, Tobias; GRAß, D.; Bigalke, Boris; Stellos, Konstantinos; Drosch, Tanja; Dietz, Klaus; Herdeg, Christian; Gawaz, Meinrad

doi:10.1111/j.1538-7836.2007.02812.x

Cited by 210 publications

(153 citation statements)

References 45 publications

Supporting

Mentioning

137

Contrasting

Unclassified

Order By: Relevance

“…These include CYP2C19 singlenucleotide polymorphisms, age, body mass index, diabetes mellitus, renal function, C-reactive protein, fibrinogen, and endothelial function. 18,[21][22][23][24][25][26] In this study, we simultaneously measured peripheral endothelial function by RHI and evaluated RPR in a population lacking CYP2C19*2 or *3 loss-offunction allele, selected specifically to avoid the effects of this gene on platelet activity. The results identified peripheral endothelial dysfunction as a significant determinant of high RPR in patients with stable CAD.…”

Section: Discussionmentioning

confidence: 99%

“…The multivariable linear regression model consisted of RHI and the variables (age, diabetes mellitus, estimated glomerular filtration rate, and Log 10 [BNP]) that had been independently shown to impact RPR in the previous studies. 18,[21][22][23][24][25][26] Each of RHI and BNP was shown as the independently associated factor for RPR (Table 2). We also analyzed the association in the 2 groups regarding the duration of clopidogrel treatment: the short-term loading group (≤7 days) and the long-term group (>7 days).…”

Section: Correlation Between Rhi and Prumentioning

confidence: 99%

See 1 more Smart Citation

Effects of Endothelial Dysfunction on Residual Platelet Aggregability After Dual Antiplatelet Therapy With Aspirin and Clopidogrel in Patients With Stable Coronary Artery Disease

Fujisue

Sugiyama

Ono

et al. 2013

Circ: Cardiovascular Interventions

View full text Add to dashboard Cite

Background-Dual antiplatelet therapy with aspirin and clopidogrel is widely used in patients with coronary stents. High residual platelet reactivity (high RPR) after dual antiplatelet therapy is associated with increased cardiovascular events. Endothelial function could affect platelet reactivity in vivo. We hypothesized that endothelial dysfunction could be associated with high RPR after dual antiplatelet therapy in patients with stable coronary artery disease. Methods and Results-We screened patients with stable coronary artery disease for cytochrome P450 (CYP) 2C19 genotypes and enrolled 103 patients who lacked CYP2C19*2 or *3 loss-of-function allele to minimize the effect of this gene on high RPR. All patients received aspirin (100 mg/d) and clopidogrel (75 mg/d for long-term treatment or a loading dose of 300 mg) before the following tests. Platelet aggregability was assessed as P2Y12 reaction unit using the VerifyNow System. High RPR was defined as P2Y12 reaction unit ≥230. Peripheral endothelial function was expressed as reactive hyperemia index using reactive hyperemia peripheral arterial tonometry. Fifty-three patients exhibited high RPR. High RPR patients were significantly older, had higher levels of B-type natriuretic peptide, and were predominantly hypertensive compared with non-high RPR patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Correlation Between Rhi and Prumentioning

confidence: 99%

Effects of Endothelial Dysfunction on Residual Platelet Aggregability After Dual Antiplatelet Therapy With Aspirin and Clopidogrel in Patients With Stable Coronary Artery Disease

Fujisue

Sugiyama

Ono

et al. 2013

Circ: Cardiovascular Interventions

View full text Add to dashboard Cite

show abstract

“…44 Similarly, ADP-induced P2Y 12 receptor assessed by various techniques was correlated with stent thrombosis and longterm post-PCI ischemic event occurrences and bleeding (Table 1). 32,44,45,[47][48][49][50][51][52][53][54][55][56][57][58][59][60][61][62][63][64][65] Some studies used receiver operating characteristic curve analysis to define an optimal cutoff of on-treatment platelet reactivity for predicting thrombotic risk. In 2010, a consensus statement proposed cutoff values based on receiver operating characteristic curve analysis for different platelet function assays to be used in future studies of personalized antiplatelet therapy.…”

Section: Relation Of Ex Vivo Platelet Function Measurement To Clinicamentioning

confidence: 99%

Platelet-Mediated Thrombosis

Gurbel

Jeong

Navarese

et al. 2016

Circulation Research

View full text Add to dashboard Cite

The pivotal role that platelets play in thrombosis and resultant ischemic event occurrences in patients with high-risk coronary artery disease is well established. This role provides the fundamental basis for the current wide implementation of dual antiplatelet therapy with aspirin and a P2Y 12 receptor inhibitor. The development of user friendly point-of-care methods to assess platelet reactivity to adenosine diphosphate has increased the frequency of platelet function testing in clinical practice. Recent large observational studies have established an independent relation between the results of point-of-care platelet function testing and clinical event occurrence in patients undergoing coronary artery stenting. However, prospective, randomized trials have failed to demonstrate that personalized antiplatelet therapy based on point-of-care assessment of platelet function is effective in reducing ischemic event occurrences. Important limitations were associated with these trials. In addition, the concept of a therapeutic window of P2Y 12 receptor reactivity with an upper threshold associated with ischemic event occurrence and a lower threshold associated with bleeding has also been proposed. In the absence of strong prospective evidence to support personalized antiplatelet therapy, clinical decision making about antiplatelet therapy rests on the large body of observational data and the fundamental importance of platelet physiology in catastrophic event occurrence in patients with high-risk coronary artery disease.

show abstract

“…Along this line, recent studies have suggested that adding clinical variables and genotype to platelet reactivity measurements (combined risk factor) will improve risk prediction. 13,68 Finally, 2 important facts should be remembered. First, the development of all antiplatelet agents has been based on an ex vivo assessment of platelet inhibition.…”

Section: Limitations Of Diagnostic Test Statistics To Describe Prognomentioning

confidence: 99%

Platelet Function Testing and Genotyping Improve Outcome in Patients Treated With Antithrombotic Agents

2012

View full text Add to dashboard Cite

The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score

Cited by 210 publications

References 45 publications

Effects of Endothelial Dysfunction on Residual Platelet Aggregability After Dual Antiplatelet Therapy With Aspirin and Clopidogrel in Patients With Stable Coronary Artery Disease

Effects of Endothelial Dysfunction on Residual Platelet Aggregability After Dual Antiplatelet Therapy With Aspirin and Clopidogrel in Patients With Stable Coronary Artery Disease

Platelet-Mediated Thrombosis

Platelet Function Testing and Genotyping Improve Outcome in Patients Treated With Antithrombotic Agents

Contact Info

Product

Resources

About